share_log

Akebia Therapeutics Analyst Ratings

Benzinga ·  Nov 17, 2023 20:06
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/17/2023 376.19% HC Wainwright & Co. $3.75 → $5 Maintains Buy
09/27/2023 257.14% HC Wainwright & Co. → $3.75 Reiterates Buy → Buy
08/28/2023 257.14% HC Wainwright & Co. $2 → $3.75 Upgrades Neutral → Buy
08/11/2023 90.48% HC Wainwright & Co. → $2 Reiterates Neutral → Neutral
06/21/2023 90.48% HC Wainwright & Co. → $2 Reiterates Neutral → Neutral
06/14/2023 90.48% HC Wainwright & Co. → $2 Reiterates Neutral → Neutral
06/02/2023 90.48% HC Wainwright & Co. → $2 Reiterates Neutral → Neutral
05/31/2023 280.95% Piper Sandler $2 → $4 Upgrades Neutral → Overweight
05/30/2023 90.48% HC Wainwright & Co. → $2 Reiterates Neutral → Neutral
05/26/2023 90.48% HC Wainwright & Co. → $2 Reiterates Neutral → Neutral
05/09/2023 90.48% Needham → $2 Reiterates → Neutral
04/26/2023 90.48% HC Wainwright & Co. $1.25 → $2 Maintains Neutral
03/31/2023 19.05% HC Wainwright & Co. → $1.25 Reiterates → Neutral
03/10/2023 19.05% HC Wainwright & Co. → $1.25 Reiterates → Neutral
02/22/2023 19.05% HC Wainwright & Co. → $1.25 Maintains Neutral
05/16/2022 19.05% HC Wainwright & Co. $2 → $1.25 Maintains Neutral
03/31/2022 90.48% HC Wainwright & Co. $10 → $2 Downgrades Buy → Neutral
03/31/2022 Needham Downgrades Buy → Hold
03/31/2022 90.48% Mizuho $6 → $2 Downgrades Buy → Neutral
03/31/2022 90.48% Piper Sandler $8 → $2 Downgrades Overweight → Neutral
11/11/2021 852.38% HC Wainwright & Co. $6 → $10 Maintains Buy
03/08/2021 661.9% Cantor Fitzgerald → $8 Initiates Coverage On → Overweight
03/08/2021 471.43% HC Wainwright & Co. $9 → $6 Maintains Buy
01/29/2021 JP Morgan Downgrades Neutral → Underweight
10/26/2020 757.14% HC Wainwright & Co. $10 → $9 Maintains Buy
09/04/2020 185.71% Morgan Stanley $12 → $3 Maintains Equal-Weight
09/04/2020 471.43% BTIG $26 → $6 Maintains Buy
09/04/2020 852.38% HC Wainwright & Co. $17 → $10 Maintains Buy
07/15/2020 1042.86% Morgan Stanley $11 → $12 Maintains Equal-Weight
05/06/2020 1614.29% JP Morgan $13 → $18 Maintains Overweight
05/06/2020 947.62% Morgan Stanley $9 → $11 Maintains Equal-Weight
05/06/2020 1519.05% HC Wainwright & Co. $16 → $17 Maintains Buy
05/06/2020 1519.05% Mizuho $15 → $17 Maintains Buy
05/05/2020 1614.29% Needham $15 → $18 Maintains Buy
03/11/2020 1328.57% Mizuho $16 → $15 Reiterates → Buy
02/20/2020 1138.1% JP Morgan $10 → $13 Maintains Overweight
11/18/2019 1423.81% HC Wainwright & Co. $17 → $16 Maintains Buy
08/06/2019 1519.05% HC Wainwright & Co. $19 → $17 Maintains Buy
05/02/2019 JP Morgan Initiates Coverage On → Overweight
03/20/2019 757.14% Citigroup → $9 Initiates Coverage On → Neutral

What is the target price for Akebia Therapeutics (AKBA)?

The latest price target for Akebia Therapeutics (NASDAQ: AKBA) was reported by HC Wainwright & Co. on November 17, 2023. The analyst firm set a price target for $5.00 expecting AKBA to rise to within 12 months (a possible 376.19% upside). 15 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Akebia Therapeutics (AKBA)?

The latest analyst rating for Akebia Therapeutics (NASDAQ: AKBA) was provided by HC Wainwright & Co., and Akebia Therapeutics maintained their buy rating.

When is the next analyst rating going to be posted or updated for Akebia Therapeutics (AKBA)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akebia Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akebia Therapeutics was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.

Is the Analyst Rating Akebia Therapeutics (AKBA) correct?

While ratings are subjective and will change, the latest Akebia Therapeutics (AKBA) rating was a maintained with a price target of $3.75 to $5.00. The current price Akebia Therapeutics (AKBA) is trading at is $1.05, which is out of the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment